Biotech News

Aptevo to Participate in March 2026 Conferences

Aptevo Therapeutics (APVO)Aptevo Therapeutics2026-03-19 12:05 ESTCompany update

SEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced its participation in the following

Aptevo Therapeutics

Multispecific Immunotherapy Platforms Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct. Mipletamig Mipletamig is a...

Recent company news

APVOAptevo Therapeutics2026-08-14 12:05 EST

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

Stock data

Close: 2.68 USD
Market cap: 6.28M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Aptevo to Participate in March 2026 Conferences

Related news

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Merit Medical to Participate in Upcoming Investors Conferences in August

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences